Clinical Trial Update: Pharmacokinetic and Injection Site Toleration of BIOD-238 and BIOD-250 Compared to Humalog® in Subjects With Type 1 Diabetes [Phase 1]

View source ↗

Summary

Phase 1 trial update reporting pharmacokinetic profiles and injection site toleration of BIOD-238 and BIOD-250 compared with Humalog (insulin lispro) in subject…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• BIOD-238
• BIOD-250
• Humalog (insulin lispro)

Snippet

Sponsor: Biodel | Conditions: Type 1 Diabetes | Phase 1 | Status: COMPLETED